Figure 1: Elevated MSI2 expression predicts poor survival in MDS.

(a) Microarray expression data (CD34⁺ population) from normal elderly individuals (CD34+; n=17) and MDS (n=183), RARS, RA, RAEB, *P<0.05, **P<0.01, ***P<0.001 Student’s t-test mean±s.e.m¹². (b) Overall survival in MDS patients stratified by MSI2 expression (as high (Z-score>1), low (Z-score<−1), or normal (−1≤Z-score≤1) log-rank test. (c). Representative flow cytometric analysis of independent patient cohort of primary patients samples gated on CD34⁺CD38⁻ and stained for intracellular MSI2, age-matched elderly individuals (n=6), low risk (RA or RARS; n=5) and high risk (RAEB-1, RAEB-2 n=10) (d). MSI2 positivity summarized from gating of patients in c. (e) MSI2 intracellular levels in the NHD13 MDS/AML animal model. Cells are initially gated on MSI2-positive cells (Supplementary Fig. 1 for gating) and median fluorescence intensity (MFI) is normalized to the control (C57BL6 mice), n=19. Pre-MDS represents the analysis preformed in NHD13 primary or transplanted mice within 1–2 months of birth and before MDS onset (n=9), the MDS mice that are older than 2 months or primary transplanted and have low WBC, (n=16) and AML samples are from NHD13 mice that have transformed to AML (n=5), d and e *P<0.05, **P<0.01, ***P<0.001 Student’s t-test horizontal line is the mean±s.e.m.